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Abstract: The X-ray structures of 12 primary selenoamides are reported. Metric 
parameters are provided, together with an illustration of the range of hydrogen bonding 
motifs. 
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Introduction 
Selenium is an essential element for life; e.g, selenocysteine is recognised as the 21st amino acid 
and the importance of selenium containing enzymes in redox processes has is now recognized [1-3]. 
Many organoselenium compounds have been studied as biological models that simulate catalytic 
functions demonstrated by natural enzymes [4-14]. For example, ebselen (I, Figure 1) acts as a 
glutathione peroxidase (GPx) mimic and as a scavenger of peroxinitrite and the activity of the sulfur 
analogue of ebselen was 15-fold lower than that of ebselen [5,6].  Selenazofurin (II) has been reported 
to be a potent inhibitor of phlebovirus infections [10]. Selenophenfurin (III) exhibits antiproliferative 
and inosine 5’-monophosphate dehydrogenase (IMPDH)-inhibition activity. Leukotrienes such as 
leukotriene B4 (LTB4) are important mediators of asthma, allergy, arthritis, psoriasis, and 
inflammatory bowel disease [11,12]. Galet et al. showed that benzoselenazolinones of type IV and the 
corresponding diselenides V dramatically decrease the formation of LTB4 [13]. Phenylseleno-
substituted pyrimidines of type VI exhibit significant inhibitory properties on Urd Pase and TMS. Se-
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methyl selenocysteine (VII) was found to be an antitumor agent, and it has been shown that β-
elimination reaction is important for this activity [14]. 
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We have a long term interest in selenium chemistry [15-20]. Woollins reagent (WR, 2,4-
bis(phenyl)-1,3-diselenadiphosphetane-2,4-diselenide, [PhP(Se)(µ-Se)]2), which is isostructural with 
the thionation agent [(p-MeOC6H4)P(S)(µ-S)]2 (Lawesson’s reagent), and may be obtained readily 
from PhPCl2, Na2Se and Se [21], is an  excellent selenation reagent for converting a range of 
unsaturated organic substrates into unusual phosphorus containing heterocycles [22-31]. We have 
recently reported the use of WR for organic transformations and for the facile synthesis of primary 
arylselenoamides from WR and ArCN [32]. Although the X-ray crystal structures of some tertiary and 
secondary selenoamides have been documented [33-39], surprisingly, no structural information has 
been published on primary arylselenoamides ArC(Se)NH2. We here provide a comparative study of a 
range of these systems. 
Results and Discussion 
Selected metric parameters for compounds A - L are given in Table 1. The C=Se bond lengths 
range from 1.822(5) to 1.856(4) Å whilst the C-N bond lengths are in the range 1.270(7) to 1.324(8) Å.   
This compares with literature values from the Cambridge Database for amide C-Se distances of 1.787-
1.885 and C-N of 1.29-1.34 Å.  The amide functionality is not particularly coplanar with the aryl 
backbone, with the selenium atom lying up to 1.406 Å from the aryl ring mean plane with the C(7)-
N(7)-Se(7) plane being up to 87o from the aryl mean plane in this case. This maximum deviation from 
coplanarity may be a function of the presence of two ortho chlorine substituents in compound L 
causing repulsion. However, it is interesting to note that in compound F the two independent 




molecules have quite different degrees of coplanarity for the selenoamide functional group and the aryl 
ring suggesting that there is little electronic reason for coplanarity.  
Figure 2. Examples of H-bonding motifs.  (a)  1 ladder  (b)  2 linked dimer  (c) 7 Herring-
bone dimers (d) 6  tetrameric sheets (e) 10 Chains (f) 9 Helical Chains.  
                     
                                (a)                                                                        (b) 
                                  (e)                                                                                  (f) 
 
Although hydrogen bonding is well understood for N-H···O and N-H···S systems, there is less data 
available for N-H···Se systems. We have previously noted that Ph2P(Se)NHP(Se)Ph2 forms dimers via 











motifs that we have observed in compounds A – L (Figure 2).  We have broadly classified the pattern 
of hydrogen bonding in compounds A - L and give selected parameters in Table 2 and provide 
illustrative examples in Figure 1. It is clear that N-H···Se hydrogen bonding is an important feature of 
the solid state packing of these molecules and may be a significant influence in biological systems. 
 
Table 1. Selected 77Se NMR data, bond lengths (Å) and angles (o) (Rows containing 
multiple entries are a.consequence of the presence of more than one independent molecule 
in the asymmetric unit). 
 δSe (ppm*) C=Se (Å) C-N (Å) Aryl/Scene interplanar angle (°) 
Deviation of Se from aryl 
Mean plane (°) 
A 602.1 1.856(4) 1.311(5) 21 0.469 
B 641.2 1.848(3) 1.314(3) 36 1.118 
C 628.6 1.829(7) 1.318(9) 27 0.619 
D 608.7 1.843(5) 1.316(7) 14 0.343 
E 579.5 1.848(5) 1.317(6) 17 0.576 
















H* 647.2 1.81(5) 1.27(7) 8-32 0.299 [-0.963] 




37 [18] 1.018 [0.361] 
J 529.0 1.829(6) 1.324(10) 39 0.786 
K 649.9 1.838(3) 1.317(4) 48 1.346 
L 715.8 1.822(5) 1.298(7) 87 1.406 
*Five independent molecules in the asymmetric unit, average bond lengths and ranges of Se 
deviations/interplanar angles are given. 
 
Table 2. Major N-H···Se hydrogen bonding distances (Å). 
 Type Se···H Se···N Se···H-N Se···H Se···N Se···H-N 
A Ladder 2.55(1) 3.512(3) 167(3) 2.72(4) 3.403(3) 127(3) 
B Linked dimers 2.527(7) 3.489(2) 168(2) 2.539(10) 3.491(2) 164(3) 
C Linked dimers 2.59(3) 3.510(6) 156(6) 2.58(3) 3.491(5) 155(5) 
D Linked dimers 
(sheets) 
2.55(1) 3.517(4) 170(5) 2.71(5) 3.408(4) 129(4) 
E Linked dimers 
(sheets) 
2.55(7) 3.527(4) 174(4) 2.82(5) 3.415(4) 120(4) 














2.68(10) 3.502(8) 142(12) 2.85(12) 3.509(8) 125(1) 
















Table 2. Cont. 












J Chain 2.52(2) 3.483(6) 168(6)    
K Dimers 2.69(1) 3.63(3) 162(3)    
L Linked dimers 2.535(8) 3.511(4) 174(5) 2.579(14) 3.533(4) 165(4) 
N-H···O hydrogen bonding: a  H···O 2.09(4) Å, N…O 3.016(7) Å, N-H…O 156(7) Å;    bH···O 
2.32(3) Å, 2.24(3) Å;  N···O 3.076(4), 2.923(3) Å; N-H···O 133(3), 126(3) Å. 
Experimental  
Primary arylselenoamides A – L (Figure 3) were prepared as described previously [32]. Their X-ray 
crystal data (Table 3) were collected at 93 K by using a Rigaku MM007 High brilliance RA 
generator/confocal optics and Mercury CCD system. Intensities were corrected for Lorentz-
polarisation and for absorption. The structures were solved by direct methods. Hydrogen atoms bound 
to carbon were idealised. Structural refinements were obtained with full-matrix least-squares based on 
F2 by using the program SHELXTL [41]. CCDC 611494 & 611495 CCDC 713559 - 713568 contain 
the supplementary crystallographic data for this paper. These data can be obtained free of charge via 
www.ccdc.cam.ac.uk/conts/retrieving.html or from the Cambridge Crystallographic Data centre, 12 
Union Road, Cambridge CB2 1EZ, UK; fax (+44) 1223-336-033; E-mail: deposit@ccdc.cam.ac.uk. 































































Table 3. Details of data collections and refinements for A - L. 
Compound  A B C D E F 
Empirical formula C8H9NOSe C8H9NSe C8H9NOSe C8H9NSe C8H9NOSe C8H6N2Se 
Crystal color, habit Yellow, prism Orange, needle Orange, prism Orange, needle Yellow, platelet Orange, needle 
Crystal dimensions/mm 0.20 × 0.15 × 0.05 
0.15 × 0.15 × 
0.08 
0.20 × 0.20 × 
0.10 
0.25 × 0.05 × 
0.01 
0.20 × 0.05 × 
0.02 
0.30 × 0.06 × 
0.03 
Crystal system Monoclinic Monoclinic Orthorhombic Monoclinic Monoclinic Orthorhombic 
Space group P2(1) / c P21(1) / c Pbca P21(1) / c P2(1) / c P2(1)2(1)2(1) 
a 5.9600(11) 7.5986(15) 8.4086(17) 9.869(2) 10.108(4) 7.4345(15) 
b 9.9600(18) 10.464(2) 11.586(2) 6.0039(13) 6.016(2) 6.0647(12) 
c 14.114(3) 10.163(2) 16.960(4) 13.658(3) 13.765(6) 34.203(6) 
β  95.506(5) 96.303(6)  105.485(6) 106.907(13)  
U/ Å3 833.9(3) 803.2(3) 1652.3(6) 779.9(3) 800.9(6) 1542.1(5) 
Z 4 4 8 4 4 8 
M 214.1 198.1 214.1 198.1 214.1 209.1 
Dc/g cm-3 1.705 1.638 1.722 1.687 1.776 1.801 
µ/mm-1 4.441 4.595 4.483 4.732 4.625 4.796 
F(000) 424 392 848 392 424 816 
Measured reflections 4447 4308 6679 2899 4170 8341 
Independent reflections (Rint) 1498 (0.0393) 1502 (0.0396) 1377 (0.0908) 1057 (0.0393) 1385 (0.0629) 2715 (0.0562) 
Final R1, wR2[I>2σ(I)] 0.0316, 0.0971 0.0269, 0.0680 0.0604, 0.1252 0.0371, 0.0924 0.0458, 0.0911 0.0752, 0.1501 
Compound  G H I J K L 
Empirical formula C7H6ClNSe C7H6BrNSe C7H6FNSe C9H11NO2Se C9H11NO2Se C9H11NO2Se 
Crystal color, habit Orange, prism Orange, prism Yellow, prism Yellow, patelet Yellow, prism Yellow, patelet 
Crystal dimentions/mm 0.30 × 0.20 × 0.05 
0.10 × 0.08 × 
0.05 
0.30 × 0.20 × 
0.10 
0.20 × 0.20 × 
0.05 
0.20 × 0.20 × 
0.15 
0.20 × 0.20 × 
0.05 
Crystal system Triclinic Triclinic Monoclinic Monoclinic Monoclinic Monoclinic 
Space group P-1 P-1 C2 / c Cc P2(1) /n Cc 
a 4.0219(8) 12.532(3) 31.874(4) 9.905(2) 10.7387(17) 9.905(2) 
b 10.774(2) 12.720(3) 3.9871(6) 14.311(3) 7.0242(11) 14.311(3) 
c 17.939(4) 17.285(6) 22.322(3) 7.1924(16) 13.539(2) 7.1924(16) 
α 92.421(6) 101.69(2) 90 90 90 90 
β  92.548(6) 99.83(2) 97.724 104.360(6) 106.225(4) 104.360(6) 
γ 91.464(6) 113.572(17) 90 90 90 90 
U/ Å3 775.6(3) 2373.8(11) 2811.1(7) 987.7(4) 980.6(3) 987.7(4) 
Z 4 12 16 4 4 4 
M 218.5 263.00 202.1 244.1 244.1 244.1 
Dc/g cm-3 1.872 2.208 1.910 1.642 1.654 1.642 
µ/mm-1 5.102 9.713 5.274 3.768 3.796 3.768 
F(000) 424 1488 1568 488 488 488 
Measured reflections 2011 4531 7115 2686 5199 2686 
Independent reflections (Rint) 1480 (0.0348) 3567 (0.0412) 2503 (0.1074) 1393 (0.0717) 1748 (0.0449) 1393(0.0717) 
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